

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

**Committee on Addressing Sickle Cell Disease:
A Strategic Plan and Blueprint for Action
September 11, 2019; Meeting #5**

**Keck Building
500 5th Street NW
Washington, DC 20001
E Street Conference Room
Agenda**

OPEN SESSION

9:00 – 10:30

Panel: SCD Therapies: products in development, the regulatory process and considerations for access

Facilitator: Enrico Novelli, M.D., Committee Member

Framing remarks: Rachel Sher, J.D., M.P.H., Vice President, Policy and Regulatory Affairs, National Organization for Rare Disorders

Bernard Dauvergne, PharmD, Executive Director, Addmedica

Brian M. Elliott, M.D., Clinical Development Medical Director, Novartis

Tony Ho, M.D., Executive Vice President of Research & Development, CRISPR Therapeutics

Ted Love, M.D., President and Chief Executive Officer, Global Blood Therapeutics

Closing Remarks and Discussion